Market Overview

Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality

Share:
Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality

Allergan plc (NYSE: AGN) needs new drivers for revenue growth, according to Morgan Stanley. Although the drugmaker's stock is inexpensive, pipeline and growth uncertainties will continue to exert pressure, the sell-side firm said in a downgrade note.

The Analyst

Morgan Stanley’s David Risinger downgraded Allergan from Overweight to Equal-Weight and reduced the price target from $183 to $156.

The Thesis

The most important pipeline candidates for Allergan are novel drugs for severe depression, Risinger said in a Wednesday note. Among these, rapastinel is scheduled for Phase III reporting in the first half of 2019.

Allergan seemed to play down this key candidate during a Jan. 29 call, the analyst said. 

There is uncertainty around the safety of ubrogepant for oral migraine, Risinger said. Although Allergan said it was pleased with the safety data, the vital details on liver toxicity are yet to be disclosed, he said. 

The company may also witness a deceleration in U.S. Botox growth, with new competition emerging, the analyst said. The implications of competitor initiatives for Botox volume and pricing are still unknown, he said. 

Morgan Stanley lowered its revenue and EPS estimates for 2019-2023 by 2-5 percent and 7-12 percent, respectively, to reflect lower pipeline projections.

Price Action

Allergan shares were down 0.84 percent at $143.90 at the time of publication Wednesday. 

Related Links:

Benzinga's Top Upgrades, Downgrades For January 30, 2019

The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

Latest Ratings for AGN

DateFirmActionFromTo
Aug 2019DowngradesBuyNeutral
Jul 2019DowngradesOutperformMarket Perform
Jul 2019DowngradesOutperformMarket Perform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (AGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
IQDowngrades
IQDowngrades21.0
COTYMaintains9.0
FNMaintains60.0
NNNMaintains57.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Tesla Earnings: Ready To Report After Workforce, Price Cut Announcements

World's Largest Company? It's Microsoft Again, And It Reports Wednesday